The e13a2 BCR‐ABL transcript negatively affects sustained deep molecular response and the achievement of treatment‐free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. Issue 10 (1st February 2019)

• Record Type: Journal Article
• Authors: D'Adda, Mariella; Farina, Mirko; Schieppati, Francesca; Borlenghi, Erika; Bottelli, Chiara; Cerqui, Elisa; Ferrari, Samantha; Gramegna, Doriana; Pagani, Chiara; Passi, Angela; Maifredi, Adriana; Tucci, Alessandra; Capucci, Maria A.; Ruggeri, Giuseppina; Rossi, Giuseppe
• Is Part Of: Cancer. Volume 125:Issue 10(2019)
• Page Start: 1674
• Page End: 1682
• Publication Date: 2019-02-01
• Subjects: breakpoint cluster region‐Abelson murine leukemia viral oncogene homolog 1 (BCR‐ABL) transcript -- chronic myelogenous leukemia -- deep molecular response -- treatment‐free remission -- tyrosine kinase inhibitors; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.31977
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : Background: Stopping tyrosine kinase inhibitor (TKI) treatment has become a realistic and safe objective for patients who have chronic myeloid leukemia (CML). Both a sustained deep molecular response (sDMR) and the lack of a molecular recurrence after TKI discontinuation are required to reach a durable treatment‐free remission (TFR). Methods: The potential predictive role of BCR‐ABL transcripts in attaining an sDMR and a TFR was analyzed in a strictly consecutive, unselected series of 194 patients who were diagnosed and treated with TKIs at the authors' center. Results: Of 173 fully evaluable patients, 67 (38.7%) had the e13a2 transcript, and 106 (61.3%) had the e14a2 transcript. Complete cytogenetic and major molecular remissions were not affected, whereas the achievement of both a DMR ( P = .008) and an sDMR ( P = .004) was favored significantly in patients who had the e14a2 transcript. After a median of 68 months, the sDMR rate was 39.6% in those with the e14a2 transcript and 19.4% in those with the e13a2 transcript. In addition to transcript type, both the early achievement of a molecular response and starting treatment with a second‐generation TKI positively affected the attainment of an sDMR in multivariate analysis. The use of a second‐generation TKI as frontline treatment increased the sDMR rate in both transcript types. However, in patients who had the e13a2 transcript, the probability of attaining an sDMR was 37% after 60 months and did not increase further despite continuing therapy. Among 51 of 60 patients who attained an sDMR after discontinuing TKIs, 24 experienced a molecular relapse, but all regained molecular remission after resuming TKI treatment. Again, transcript type influenced TFR maintenance ( P = .005), because only 2 patients (3%) with the e13a2 transcript enjoyed a durable TFR compared with 25 (23.5%) of those with the e14a2 transcript. Conclusions: The e13a2 transcript hinders the achievement of deep responses and the possibility of stopping TKI treatment in patients with CML. Abstract : Among patients who have chronic myeloid leukemia and receive treatment with tyrosine kinase inhibitors, the likelihood of obtaining a sustained deep molecular response and a durable treatment‐free remission is lower in those who have the e13a2 BCR‐ABL transcript. After 5 years of treatment, the probability that patients with the e13a2 transcript will achieve a sustained deep molecular response is 17.4% with imatinib and 36.2% with second‐generation tyrosine kinase inhibitors.